(SYK) Stryker - Ratings and Ratios
Joints, Implants, Robotics, Surgical Tools, Neuro Devices
SYK EPS (Earnings per Share)
SYK Revenue
Description: SYK Stryker
Stryker Corporation is a leading medical technology company operating through two main segments: MedSurg and Neurotechnology, and Orthopaedics. The company offers a diverse range of products and technologies, including surgical equipment, navigation systems, implants for joint replacements, and orthobiologic products. Strykers products are sold globally to healthcare facilities through a combination of company-owned subsidiaries and third-party distributors.
From a business perspective, Strykers strength lies in its diversified product portfolio and global reach, with operations in approximately 75 countries. The companys Orthopaedics segment is a significant contributor, with a strong presence in the joint replacement market. Additionally, Strykers MedSurg and Neurotechnology segment is well-positioned for growth, driven by increasing demand for minimally invasive surgical procedures and advancements in neurotechnology.
Some key performance indicators (KPIs) to monitor Strykers performance include revenue growth, gross margin expansion, and return on equity (RoE). With a current RoE of 14.04%, Stryker demonstrates a reasonable return on shareholder equity. Other relevant KPIs include the companys operating margin, which can indicate its ability to maintain pricing power and manage costs, and its research and development (R&D) expenditure as a percentage of sales, which can signal its commitment to innovation and future growth.
To further analyze Strykers stock, we can examine its valuation multiples. With a forward price-to-earnings (P/E) ratio of 29.50, the stock appears to be reasonably valued compared to its expected earnings growth. Additionally, the companys dividend yield and payout ratio can be monitored to assess its ability to return capital to shareholders. By analyzing these KPIs and valuation multiples, investors can gain a more comprehensive understanding of Strykers financial health and growth prospects.
SYK Stock Overview
| Market Cap in USD | 147,123m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1988-02-01 |
SYK Stock Ratings
| Growth Rating | 67.0% |
| Fundamental | 66.2% |
| Dividend Rating | 60.4% |
| Return 12m vs S&P 500 | -6.19% |
| Analyst Rating | 4.06 of 5 |
SYK Dividends
| Dividend Yield 12m | 1.08% |
| Yield on Cost 5y | 2.21% |
| Annual Growth 5y | 6.59% |
| Payout Consistency | 96.6% |
| Payout Ratio | 25.8% |
SYK Growth Ratios
| Growth Correlation 3m | 21.6% |
| Growth Correlation 12m | 54.1% |
| Growth Correlation 5y | 86.8% |
| CAGR 5y | 15.76% |
| CAGR/Max DD 5y | 0.50 |
| Sharpe Ratio 12m | -0.55 |
| Alpha | -0.67 |
| Beta | 0.480 |
| Volatility | 21.18% |
| Current Volume | 1028.6k |
| Average Volume 20d | 1117.3k |
| Stop Loss | 377.9 (-3%) |
| Signal | -0.58 |
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (2.92b TTM) > 0 and > 6% of Revenue (6% = 1.43b TTM) |
| FCFTA 0.09 (>2.0%) and ΔFCFTA 1.52pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 23.99% (prev 22.06%; Δ 1.93pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.11 (>3.0%) and CFO 5.02b > Net Income 2.92b (YES >=105%, WARN >=100%) |
| Net Debt (14.75b) to EBITDA (4.61b) ratio: 3.20 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.78 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (386.4m) change vs 12m ago 0.26% (target <= -2.0% for YES) |
| Gross Margin 62.19% (prev 61.21%; Δ 0.98pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 55.74% (prev 54.66%; Δ 1.08pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 22.08 (EBITDA TTM 4.61b / Interest Expense TTM 159.0m) >= 6 (WARN >= 3) |
Altman Z'' 3.51
| (A) 0.12 = (Total Current Assets 13.00b - Total Current Liabilities 7.29b) / Total Assets 46.33b |
| (B) 0.42 = Retained Earnings (Balance) 19.42b / Total Assets 46.33b |
| (C) 0.08 = EBIT TTM 3.51b / Avg Total Assets 42.73b |
| (D) 0.74 = Book Value of Equity 18.70b / Total Liabilities 25.14b |
| Total Rating: 3.51 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 66.19
| 1. Piotroski 7.0pt = 2.0 |
| 2. FCF Yield 2.49% = 1.25 |
| 3. FCF Margin 16.89% = 4.22 |
| 4. Debt/Equity 0.79 = 2.20 |
| 5. Debt/Ebitda 3.63 = -2.40 |
| 6. ROIC - WACC 1.21% = 1.51 |
| 7. RoE 14.08% = 1.17 |
| 8. Rev. Trend 84.88% = 4.24 |
| 9. Rev. CAGR 11.37% = 1.42 |
| 10. EPS Trend 12.55% = 0.31 |
| 11. EPS CAGR 2.51% = 0.25 |
What is the price of SYK shares?
Over the past week, the price has changed by +1.26%, over one month by -2.75%, over three months by +2.66% and over the past year by +10.40%.
Is Stryker a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of SYK is around 404.69 USD . This means that SYK is currently overvalued and has a potential downside of 3.85%.
Is SYK a buy, sell or hold?
- Strong Buy: 13
- Buy: 9
- Hold: 9
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the SYK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 432.3 | 10.9% |
| Analysts Target Price | 421.5 | 8.2% |
| ValueRay Target Price | 445.4 | 14.3% |
Last update: 2025-08-23 05:05
SYK Fundamental Data Overview
CCE Cash And Equivalents = 2.38b USD (last quarter)
P/E Trailing = 51.0385
P/E Forward = 29.2398
P/S = 6.177
P/B = 7.0697
P/EG = 2.229
Beta = 0.914
Revenue TTM = 23.82b USD
EBIT TTM = 3.51b USD
EBITDA TTM = 4.61b USD
Long Term Debt = 14.83b USD (from longTermDebt, last quarter)
Short Term Debt = 1.91b USD (from shortTermDebt, last quarter)
Debt = 16.74b USD (Calculated: Short Term 1.91b + Long Term 14.83b)
Net Debt = 14.75b USD (from netDebt column, last quarter)
Enterprise Value = 161.49b USD (147.12b + Debt 16.74b - CCE 2.38b)
Interest Coverage Ratio = 22.08 (Ebit TTM 3.51b / Interest Expense TTM 159.0m)
FCF Yield = 2.49% (FCF TTM 4.02b / Enterprise Value 161.49b)
FCF Margin = 16.89% (FCF TTM 4.02b / Revenue TTM 23.82b)
Net Margin = 12.25% (Net Income TTM 2.92b / Revenue TTM 23.82b)
Gross Margin = 62.19% ((Revenue TTM 23.82b - Cost of Revenue TTM 9.01b) / Revenue TTM)
Tobins Q-Ratio = 8.64 (Enterprise Value 161.49b / Book Value Of Equity 18.70b)
Interest Expense / Debt = 0.95% (Interest Expense 159.0m / Debt 16.74b)
Taxrate = 14.29% (from yearly Income Tax Expense: 499.0m / 3.49b)
NOPAT = 3.01b (EBIT 3.51b * (1 - 14.29%))
Current Ratio = 1.78 (Total Current Assets 13.00b / Total Current Liabilities 7.29b)
Debt / Equity = 0.79 (Debt 16.74b / last Quarter total Stockholder Equity 21.19b)
Debt / EBITDA = 3.63 (Net Debt 14.75b / EBITDA 4.61b)
Debt / FCF = 4.16 (Debt 16.74b / FCF TTM 4.02b)
Total Stockholder Equity = 20.73b (last 4 quarters mean)
RoA = 6.30% (Net Income 2.92b, Total Assets 46.33b )
RoE = 14.08% (Net Income TTM 2.92b / Total Stockholder Equity 20.73b)
RoCE = 9.87% (Ebit 3.51b / (Equity 20.73b + L.T.Debt 14.83b))
RoIC = 8.28% (NOPAT 3.01b / Invested Capital 36.34b)
WACC = 7.07% (E(147.12b)/V(163.86b) * Re(7.78%)) + (D(16.74b)/V(163.86b) * Rd(0.95%) * (1-Tc(0.14)))
Shares Correlation 5-Years: 90.0 | Cagr: 0.24%
Discount Rate = 7.78% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 81.00% ; FCFE base≈3.54b ; Y1≈4.23b ; Y5≈6.71b
Fair Price DCF = 300.1 (DCF Value 114.72b / Shares Outstanding 382.3m; 5y FCF grow 20.87% → 3.0% )
Revenue Correlation: 84.88 | Revenue CAGR: 11.37%
Rev Growth-of-Growth: 0.73
EPS Correlation: 12.55 | EPS CAGR: 2.51%
EPS Growth-of-Growth: -26.52
Additional Sources for SYK Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle